ReviewFrontiers in bioengineering and biotechnology2026
Erythropoietin in tissue engineering and beyond: a multifunctional macromolecule with emerging roles in organoids, immune modulation, and cancer research.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythropoietin (EPO), a glycoprotein hormone conventionally associated with erythropoiesis, has emerged as a versatile macromolecule with substantial therapeutic potential in tissue engineering and regenerative medicine. Beyond its role in red blood cell production, EPO displays pleiotropic effects, including angiogenesis, neuroprotection, anti-apoptosis, immunomodulation, and cell survival, making it a suitable agent for tissue repair and regeneration. This review explores EPO's biological characteristics and its integration into tissue-engineered constructs through innovative approaches such as scaffold immobilization, hydrogel encapsulation, and genetically modified cells for localized delivery. EPO has shown remarkable efficacy in regenerating diverse tissues, including bone, cartilage, neural, cardiac, dental, and skin, and in promoting wound healing. Additionally, its applications extend to advanced fields such as organoid development, immune modulation, and cancer research, further highlighting its versatility. Nevertheless, challenges such as maintaining EPO's bioactivity, achieving controlled and sustained delivery, and mitigating systemic or off-target effects remain significant barriers. Furthermore, its dual role in cancer biology necessitates a deeper understanding of its effects on tumor growth and immunity. Future advances in biomaterials and precision medicine could optimize EPO-based delivery systems to enable personalized therapeutic solutions. EPO stands poised to revolutionize tissue engineering, thus bridging laboratory innovation and clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.